Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Shares Issued (2016 - 2024)

Historic Shares Issued for Fate Therapeutics (FATE) over the last 12 years, with Q2 2024 value amounting to -$662000.0.

  • Fate Therapeutics' Shares Issued fell 124137.93% to -$662000.0 in Q2 2024 from the same period last year, while for Mar 2025 it was -$662000.0, marking a year-over-year decrease of 10088.18%. This contributed to the annual value of $74.5 million for FY2024, which is 8758352.94% up from last year.
  • Per Fate Therapeutics' latest filing, its Shares Issued stood at -$662000.0 for Q2 2024, which was down 124137.93% from $75.2 million recorded in Q1 2024.
  • Fate Therapeutics' Shares Issued's 5-year high stood at $75.2 million during Q1 2024, with a 5-year trough of -$138.8 million in Q4 2020.
  • Its 5-year average for Shares Issued is $968764.7, with a median of $1.5 million in 2022.
  • Per our database at Business Quant, Fate Therapeutics' Shares Issued crashed by 10196544.12% in 2020 and then surged by 3622512.08% in 2024.
  • Fate Therapeutics' Shares Issued (Quarter) stood at -$138.8 million in 2020, then soared by 100.02% to $34000.0 in 2021, then skyrocketed by 4361.76% to $1.5 million in 2022, then plummeted by 111.87% to -$180000.0 in 2023, then tumbled by 267.78% to -$662000.0 in 2024.
  • Its Shares Issued stands at -$662000.0 for Q2 2024, versus $75.2 million for Q1 2024 and -$180000.0 for Q4 2023.